Prime Medicine (PRME) Net Income towards Common Stockholders (2021 - 2026)

Prime Medicine (PRME) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$49.1 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 5.33% year-over-year to -$49.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$198.4 million (up 1.8% YoY) and the FY2025 annual result came in at -$201.1 million, down 2.69% from the prior year.
• Net Income towards Common Stockholders slipped to -$49.1 million in Q1 2026, from -$46.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$30.1 million in Q1 2022 to a low of -$65.6 million in Q4 2023.
• A 5-year average of -$46.3 million and a median of -$46.1 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders surged 41.4% — and 2023, when it slumped 61.69%.
• Tracing PRME's Net Income towards Common Stockholders over 5 years: stood at -$40.6 million in 2022, then tumbled by 61.69% to -$65.6 million in 2023, then soared by 35.6% to -$42.3 million in 2024, then decreased by 9.0% to -$46.1 million in 2025, then slipped by 6.6% to -$49.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$49.1 million (Q1 2026), -$46.1 million (Q4 2025), and -$50.6 million (Q3 2025), per Business Quant data.